{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:40:12Z","timestamp":1759624812384,"version":"build-2065373602"},"reference-count":10,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["revistaalergia.mx"],"crossmark-restriction":false},"short-container-title":["Rev. Alergia Mex"],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:p>Methods: Patients with HAE type I\/II, aged \u226512 years, were included from the EMPOWER and ENABLE studies, who received lanadelumab at the approved dose and had data on the initial attack rate. Subgroups were created based on baseline HAE activity (moderate: \u22651 to &lt;2, high: \u22652 to &lt;3, very high: \u22653 attacks\/month). The effectiveness of lanadelumab was measured by the reduction in monthly attacks compared to baseline. Safety was assessed by treatment-emergent adverse events (TEAEs).\n\nResults: A total of 123 patients were analyzed, divided into subgroups by baseline activity: moderate (29), high (15), and very high (79). The mean follow-up duration ranged from 577.5 \u00b1 251.7 days (moderate) to 741.1 \u00b1 281.0 days (high). Average HAE attack rates decreased in all three subgroups after lanadelumab initiation: moderate (1.3 \u00b1 0.3 to 0.3 \u00b1 0.4), high (2.0 \u00b1 0.2 to 0.5 \u00b1 0.5), and very high (5.8 \u00b1 3.0 to 0.4 \u00b1 0.7). TEAEs were not severe, mild\/moderate, and unrelated to lanadelumab treatment.\n\nConclusion: HAE attack rates decreased after lanadelumab initiation, regardless of baseline activity. Safety was similar across groups; most TEAEs were mild and unrelated to treatment. These data support lanadelumab as a first-line option for long-term prophylaxis.\n\nKeywords: Lanadelumab; EMPOWER; Enable; Hereditary angioedema; Disease activity.<\/jats:p>","DOI":"10.29262\/ram.v72i3.1505","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:19:00Z","timestamp":1759241940000},"update-policy":"https:\/\/doi.org\/10.29262\/ram.crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER\/ENABLE"],"prefix":"10.29262","volume":"72","author":[{"given":"Juan Carlos","family":"Rodriguez Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"62613","unstructured":"REFERENCIAS:"},{"key":"62614","doi-asserted-by":"crossref","unstructured":"1. Manning ME. DermatolTher(Heidelb) 2021;11:1829-1838.","DOI":"10.1007\/s13555-021-00593-x"},{"key":"62615","unstructured":"2.Takeda PharmaceuticalCompany Limited. Takhzyro (lanadelumab-flyo) injection, forsubcutaneoususe. Highlightsofprescribinginformation."},{"key":"62616","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761090s010lbl.pdf.Accessed1 October2024."},{"key":"62617","unstructured":"3.Takeda PharmaceuticalsInternational AG IrelandBranch. Takhzyro, INN-lanadelumab. Summaryofproduct"},{"key":"62618","unstructured":"characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/takhzyro-epar-product-information_en.pdf. Accessed1 October2024."},{"key":"62619","unstructured":"4.A StudyofLanadelumabin PersonsWithHereditaryAngioedema (HAE) TypeI orII in North America(EMPOWER) (NCT03845400)."},{"key":"62620","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03845400. Accessed1 October2024."},{"key":"62621","unstructured":"5.A StudyofLanadelumabin PersonsWithHereditaryAngioedema (HAE) TypeI orII (ENABLE) (NCT04130191).https:\/\/clinicaltrials.gov\/study\/NCT04130191."},{"key":"62622","unstructured":"Accessed1 October2024."}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1505\/2758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1505\/2758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:43:35Z","timestamp":1759592615000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i3.1505","relation":{},"ISSN":["0002-5151","2448-9190"],"issn-type":[{"type":"print","value":"0002-5151"},{"type":"electronic","value":"2448-9190"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}